Blank Bio
ActiveHiringRNA intelligence for precision medicine
About
Blank Bio is an applied AI research lab focused on increasing the success rates of clinical trials. We do this by training RNA foundation models that learn the patterns that shape disease progression and patient response to treatment. We aim to help pharma make more informed decisions in clinical trials by capturing the biology that makes each patient’s tumour unique. We’re a technical team of AI scientists and engineers from companies including Recursion, Deep Genomics, DeepMind, and Amazon, and institutions including Memorial Sloan Kettering Cancer Centre, Stanford, and the Vector Institute.
Founders
Jonny Hsu· FounderWorking on foundation models for RNA therapeutics. I was an early employee at Valence Discovery, a biotech startup that spun out from Mila. I led product and strategy. Valence was acquired by Recursion (NASDAQ: RXRX) in May 2023. I stayed on afterwards to help build out the AI research engine of Recursion called Valence Labs. Biochemist by training | Waterloo graduate
Philip Fradkin· FounderBuilding AI for the most designable molecule in the world: RNA Published at top ML & Bio conferences including best paper at Foundation models for science @ Neurips. Built self-supervised learning applications for RNA, small molecules, and phenomics. Playing long term games in ML for Biology. One of the first employees at Deep Genomics. PhD from University of Toronto.
- Ian Shi· Founder
Building foundational models for RNA therapeutics at Blank Bio. Just defended my PhD in CS at the University of Toronto. Published at ICML, NeurIPS, Nature Comms; used 4 GPUs to pre-train an mRNA foundation model that beat competitors using months of compute on thousands of H100s. Now scaling our models to unlock new possibilities in the RNA therapeutic space. Previously at Amazon building software, interned at Pinterest and Amazon as a research scientist in between.
Product launches · 1 launch
Building foundation models to design better RNA therapeutics, starting with mRNA design.